Connect with us

International

The Valorization Of The Tyrants

The Valorization Of The Tyrants

Authored by Jeffrey Tucker via The Epoch Times,

This is surely one of the strangest twists in official narratives…

Published

on

The Valorization Of The Tyrants

Authored by Jeffrey Tucker via The Epoch Times,

This is surely one of the strangest twists in official narratives in perhaps hundreds of years. The bad guys have been christened as the good guys, and the good guys have been purged, deplatformed, canceled, and demonized.

It’s a turn of events none of us could have imagined back in 2020. It cries out for an explanation. I truly fear knowing the answer as to why.

Just consider the fate of former New Zealand Prime Jacinda Ardern.

She locked down her country, trampling all rights of the people under the guise of controlling the spread of a virus. You could not go to church. You could not be unmasked. You could not leave the country and return. No one could travel there without official permission.

As bad as the United States and Europe were during this period, New Zealand was worse, and it was backed up by speech controls. Anyone protesting the policies was risking everything. And when the vaccine came along, Ardern outright said it: the people who get it will have rights but those who do not will not. It was a new biomedical caste system.

Eventually, the country did open. Now speakers decrying the whole period are attracting audiences in the thousands, and Ardern is widely unpopular. Her successor who continues to defend all this despotism is under a cloud and also deeply unpopular. The tables have completely turned. Of course the virus came anyway, as it must, so the junta that did this has turned their attention to climate change, the defense of censorship, and the escalation of the Russia/Ukraine war.

Five years ago, anyone would have supposed that a leader that acted this way would live in shame. I certainly assumed so. My supposition is that Ardern had made horrific misjudgments and would be widely decried as a confused tyrant. She would live out her days in disrepute, surely.

The opposite has happened. She is now the subject of celebratory biographies. She is lauded by mainstream media. She addressed the United Nations last year in a speech that was an open call for a new global censorship regime. True, the fact-checkers disagree with this interpretation. Instead she was merely calling out “the weaponization of free speech societies and platforms by misinformation agents.”

Oh.

In any case, in my imagination, I could not have dreamed up a specimen of error and tyranny more deserving of devaluing than Jacinda Ardern. Everything she did during the COVID era flies in the face of values that the West has held for almost a thousand years since the Magna Carta.

But I was wrong. Completely. I underestimated just how broken the world is. Instead of being disgraced, she is enjoying not one but two fellowships at Harvard University where she enjoys massive prestige and adoration by faculty, staff, and students. To me, this seems like the Twilight Zone—an ending to the story that I could not have imagined. Are we supposed to be against segregation, house arrest, forced medical treatments, locking people in nations, and censorship? I thought at least we would agree on that much. Apparently not. Apparently, it is the opposite. Everything that I believed was deprecated is exalted and all the public virtues I believed we extolled are now denounced.

It’s not just Ardern. The whole tiny but global junta that imposed all these policies seemed to be enjoying a glorious send-off by the entire establishment, even though they have been 100 percent wrong about everything. Fauci’s successor is Fauci II, and same with Walensky’s successor at the CDC. And the media propagandists who for three years lied to the public about lockdowns, masks, school closures, and shots are now writing books that are calling people like me the bad guys!

I almost cannot imagine that this has happened and I cannot fathom why.

As another example, the New York Times op-ed page has carried an amazing and very long article by Yoel Roth, the former chief censor of Twitter 1.0 before he was summarily fired by Elon Musk. The Times let him tell his tale of woe on how oppressed and beaten down he is merely for enforcing trust and safety. He was only doing his job to stop online lies!

The Twitter Files revealed that the company was obeying government priorities and blocking and throttling content that took issue with COVID policies, questions surrounding election integrity, and vaccine effectiveness. Roth, in cooperation with federal agencies, set himself up as the arbiter of truth and arguably distorted information flows based on his personal bias.

Like Ardern, I might have expected that he would retire from public life and deploy his considerable communication for a small company somewhere. But I was wrong again. Instead he holds a coveted position at the University of Pennsylvania and the Carnegie Endowment for International Peace.

For that matter, Anthony Fauci himself is enjoying a comfy sinecure at Georgetown University.

This is not just about how high-end academia has become a haven for woke politics, censorship, and wildly pro-statist thinking across the board. That battle seems to have been won by the bad guys perhaps two decades ago. The problem is much larger. It has to do with the entire academic, corporate, political, and deep-state establishment that was heavily involved in imposing a despotic turn for the entire globe.

They are right now in the business of protecting their own, trolling the rest of us by granting awards and honors to the absolute worst offenders of core Western values. It’s like the world has been turned upside down. As grim as I believed the lockdowns that began in March 2020 were, and as much as I expected some terrible economic and cultural fallout from that period, I never would have imagined that the lockdowners and mandaters would be riding high at 42 months of this.

And at the very same time, the purges of the people who were right all along are continuing at a furious pace. Every day, we observe sneaky attacks on the greatest champions of basic liberties on which I thought everyone agreed back in 2019. Every unflattering bit of personal information on the resistors is fair game, amplified by the media, and then realized in the form of demonetizations by Big Tech, the courts, and the professional circuit generally.

The battle lines are very clear and only one side stands for the rights and liberties for which humanity worked for a millennium. The other side stands for controls, impositions, divisions, surveillance, censorship, degrowth, and corporate cartelizations. Can someone explain to me why we are supposed to think that the bad guys are now the good guys? In short, how can we account for the valorization of tyrants?

Tyler Durden Thu, 09/21/2023 - 23:40

Read More

Continue Reading

International

Four burning questions about the future of the $16.5B Novo-Catalent deal

To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both.
Beyond spending billions of dollars to expand…

Published

on

To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both.

Beyond spending billions of dollars to expand its own production capacity for its weight loss drugs, the Danish drugmaker said Monday it will pay $11 billion to acquire three manufacturing plants from Catalent. It’s part of a broader $16.5 billion deal with Novo Holdings, the investment arm of the pharma’s parent group, which agreed to acquire the contract manufacturer and take it private.

It’s a big deal for all parties, with potential ripple effects across the biotech ecosystem. Here’s a look at some of the most pressing questions to watch after Monday’s announcement.

Why did Novo do this?

Novo Holdings isn’t the most obvious buyer for Catalent, particularly after last year’s on-and-off M&A interest from the serial acquirer Danaher. But the deal could benefit both Novo Holdings and Novo Nordisk.

Novo Nordisk’s biggest challenge has been simply making enough of the weight loss drug Wegovy and diabetes therapy Ozempic. On last week’s earnings call, Novo Nordisk CEO Lars Fruergaard Jørgensen said the company isn’t constrained by capital in its efforts to boost manufacturing. Rather, the main challenge is the limited amount of capabilities out there, he said.

“Most pharmaceutical companies in the world would be shopping among the same manufacturers,” he said. “There’s not an unlimited amount of machinery and people to build it.”

While Novo was already one of Catalent’s major customers, the manufacturer has been hamstrung by its own balance sheet. With roughly $5 billion in debt on its books, it’s had to juggle paying down debt with sufficiently investing in its facilities. That’s been particularly challenging in keeping pace with soaring demand for GLP-1 drugs.

Novo, on the other hand, has the balance sheet to funnel as much money as needed into the plants in Italy, Belgium, and Indiana. It’s also struggled to make enough of its popular GLP-1 drugs to meet their soaring demand, with documented shortages of both Ozempic and Wegovy.

The impact won’t be immediate. The parties expect the deal to close near the end of 2024. Novo Nordisk said it expects the three new sites to “gradually increase Novo Nordisk’s filling capacity from 2026 and onwards.”

As for the rest of Catalent — nearly 50 other sites employing thousands of workers — Novo Holdings will take control. The group previously acquired Altasciences in 2021 and Ritedose in 2022, so the Catalent deal builds on a core investing interest in biopharma services, Novo Holdings CEO Kasim Kutay told Endpoints News.

Kasim Kutay

When asked about possible site closures or layoffs, Kutay said the team hasn’t thought about that.

“That’s not our track record. Our track record is to invest in quality businesses and help them grow,” he said. “There’s always stuff to do with any asset you own, but we haven’t bought this company to do some of the stuff you’re talking about.”

What does it mean for Catalent’s customers? 

Until the deal closes, Catalent will operate as a standalone business. After it closes, Novo Nordisk said it will honor its customer obligations at the three sites, a spokesperson said. But they didn’t answer a question about what happens when those contracts expire.

The wrinkle is the long-term future of the three plants that Novo Nordisk is paying for. Those sites don’t exclusively pump out Wegovy, but that could be the logical long-term aim for the Danish drugmaker.

The ideal scenario is that pricing and timelines remain the same for customers, said Nicole Paulk, CEO of the gene therapy startup Siren Biotechnology.

Nicole Paulk

“The name of the group that you’re going to send your check to is now going to be Novo Holdings instead of Catalent, but otherwise everything remains the same,” Paulk told Endpoints. “That’s the best-case scenario.”

In a worst case, Paulk said she feared the new owners could wind up closing sites or laying off Catalent groups. That could create some uncertainty for customers looking for a long-term manufacturing partner.

Are shareholders and regulators happy? 

The pandemic was a wild ride for Catalent’s stock, with shares surging from about $40 to $140 and then crashing back to earth. The $63.50 share price for the takeover is a happy ending depending on the investor.

On that point, the investing giant Elliott Investment Management is satisfied. Marc Steinberg, a partner at Elliott, called the agreement “an outstanding outcome” that “clearly maximizes value for Catalent stockholders” in a statement.

Elliott helped kick off a strategic review last August that culminated in the sale agreement. Compared to Catalent’s stock price before that review started, the deal pays a nearly 40% premium.

Alessandro Maselli

But this is hardly a victory lap for CEO Alessandro Maselli, who took over in July 2022 when Catalent’s stock price was north of $100. Novo’s takeover is a tacit acknowledgment that Maselli could never fully right the ship, as operational problems plagued the company throughout 2023 while it was limited by its debt.

Additional regulatory filings in the next few weeks could give insight into just how competitive the sale process was. William Blair analysts said they don’t expect a competing bidder “given the organic investments already being pursued at other leading CDMOs and the breadth and scale of Catalent’s operations.”

The Blair analysts also noted the companies likely “expect to spend some time educating relevant government agencies” about the deal, given the lengthy closing timeline. Given Novo Nordisk’s ascent — it’s now one of Europe’s most valuable companies — paired with the limited number of large contract manufacturers, antitrust regulators could be interested in taking a close look.

Are Catalent’s problems finally a thing of the past?

Catalent ran into a mix of financial and operational problems over the past year that played no small part in attracting the interest of an activist like Elliott.

Now with a deal in place, how quickly can Novo rectify those problems? Some of the challenges were driven by the demands of being a publicly traded company, like failing to meet investors’ revenue expectations or even filing earnings reports on time.

But Catalent also struggled with its business at times, with a range of manufacturing delays, inspection reports and occasionally writing down acquisitions that didn’t pan out. Novo’s deep pockets will go a long way to a turnaround, but only the future will tell if all these issues are fixed.

Kutay said his team is excited by the opportunity and was satisfied with the due diligence it did on the company.

“We believe we’re buying a strong company with a good management team and good prospects,” Kutay said. “If that wasn’t the case, I don’t think we’d be here.”

Amber Tong and Reynald Castañeda contributed reporting.

Read More

Continue Reading

International

Petrina Kamya, Ph.D., Head of AI Platforms at Insilico Medicine, presents at BIO CEO & Investor Conference

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb….

Published

on

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb. 26-27 at the New York Marriott Marquis in New York City. Dr. Kamya will speak as part of the panel “AI within Biopharma: Separating Value from Hype,” on Feb. 27, 1pm ET along with Michael Nally, CEO of Generate: Biomedicines and Liz Schwarzbach, PhD, CBO of BigHat Biosciences.

Credit: Insilico Medicine

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb. 26-27 at the New York Marriott Marquis in New York City. Dr. Kamya will speak as part of the panel “AI within Biopharma: Separating Value from Hype,” on Feb. 27, 1pm ET along with Michael Nally, CEO of Generate: Biomedicines and Liz Schwarzbach, PhD, CBO of BigHat Biosciences.

The session will look at how the latest artificial intelligence (AI) tools – including generative AI and large language models – are currently being used to advance the discovery and design of new drugs, and which technologies are still in development. 

The BIO CEO & Investor Conference brings together over 1,000 attendees and more than 700 companies across industry and institutional investment to discuss the future investment landscape of biotechnology. Sessions focus on topics such as therapeutic advancements, market outlook, and policy priorities.

Insilico Medicine is a leading, clinical stage AI-driven drug discovery company that has raised over $400m in investments since it was founded in 2014. Dr. Kamya leads the development of the Company’s end-to-end generative AI platform, Pharma.AI from Insilico’s AI R&D Center in Montreal. Using modern machine learning techniques in the context of chemistry and biology, the platform has driven the discovery and design of 30+ new therapies, with five in clinical stages – for cancer, fibrosis, inflammatory bowel disease (IBD), and COVID-19. The Company’s lead drug, for the chronic, rare lung condition idiopathic pulmonary fibrosis, is the first AI-designed drug for an AI-discovered target to reach Phase II clinical trials with patients. Nine of the top 20 pharmaceutical companies have used Insilico’s AI platform to advance their programs, and the Company has a number of major strategic licensing deals around its AI-designed therapeutic assets, including with Sanofi, Exelixis and Menarini. 

 

About Insilico Medicine

Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com 


Read More

Continue Reading

International

Another country is getting ready to launch a visa for digital nomads

Early reports are saying Japan will soon have a digital nomad visa for high-earning foreigners.

Published

on

Over the last decade, the explosion of remote work that came as a result of improved technology and the pandemic has allowed an increasing number of people to become digital nomads. 

When looked at more broadly as anyone not required to come into a fixed office but instead moves between different locations such as the home and the coffee shop, the latest estimate shows that there were more than 35 million such workers in the world by the end of 2023 while over half of those come from the United States.

Related: There is a new list of cities that are best for digital nomads

While remote work has also allowed many to move to cheaper places and travel around the world while still bringing in income, working outside of one's home country requires either dual citizenship or work authorization — the global shift toward remote work has pushed many countries to launch specific digital nomad visas to boost their economies and bring in new residents.

Japan is a very popular destination for U.S. tourists. 

Shutterstock

This popular vacation destination will soon have a nomad visa

Spain, Portugal, Indonesia, Malaysia, Costa Rica, Brazil, Latvia and Malta are some of the countries currently offering specific visas for foreigners who want to live there while bringing in income from abroad.

More Travel:

With the exception of a few, Asian countries generally have stricter immigration laws and were much slower to launch these types of visas that some of the countries with weaker economies had as far back as 2015. As first reported by the Japan Times, the country's Immigration Services Agency ended up making the leap toward a visa for those who can earn more than ¥10 million ($68,300 USD) with income from another country.

The Japanese government has not yet worked out the specifics of how long the visa will be valid for or how much it will cost — public comment on the proposal is being accepted throughout next week. 

That said, early reports say the visa will be shorter than the typical digital nomad option that allows foreigners to live in a country for several years. The visa will reportedly be valid for six months or slightly longer but still no more than a year — along with the ability to work, this allows some to stay beyond the 90-day tourist period typically afforded to those from countries with visa-free agreements.

'Not be given a residence card of residence certificate'

While one will be able to reapply for the visa after the time runs out, this can only be done by exiting the country and being away for six months before coming back again — becoming a permanent resident on the pathway to citizenship is an entirely different process with much more strict requirements.

"Those living in Japan with the digital nomad visa will not be given a residence card or a residence certificate, which provide access to certain government benefits," reports the news outlet. "The visa cannot be renewed and must be reapplied for, with this only possible six months after leaving the countr

The visa will reportedly start in March and also allow holders to bring their spouses and families with them. To start using the visa, holders will also need to purchase private health insurance from their home country while taxes on any money one earns will also need to be paid through one's home country.

Read More

Continue Reading

Trending